667, L.P., Director, 10% Owner at TScan Therapeutics, Inc. (TCRX), bought 2,545,090 shares at $1.70 ($4.8M) on 2022-05-10, disclosed to the SEC on 2022-05-12.
Open-market purchase of $4.8M TCRX by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.70 | 40,800 | $69K | 1.4% |
| 2 | $1.70 | 325,373 | $553K | 11.6% |
| 3 | $1.70 | 325,373 | $553K | 11.6% |
| 4 | $1.93 | 12,769 | $25K | 0.5% |
| 5 | $1.93 | 101,831 | $197K | 4.1% |
| 6 | $1.93 | 101,831 |
| $197K |
| 4.1% |
| 7 | $1.95 | 95,060 | $185K | 3.9% |
| 8 | $1.95 | 758,094 | $1.5M | 30.9% |
| 9 | $1.95 | 758,094 | $1.5M | 30.9% |
| 10 | $1.99 | 2,882 | $6K | 0.1% |
| 11 | $1.99 | 22,983 | $46K | 1.0% |
| Total | $1.88 avg | 2,545,090 | $4.8M | 100% |
| Filing → |
| MDGL | BUY | 2023-12-14 | $14.7M | — | Filing → |
| ACAD | BUY | 2023-05-24 | $45.4M | — | Filing → |
| IGMS | BUY | 2022-04-05 | $65.0M | — | Filing → |